Beyond simple diagnostics, theranostics is intended to give clinicians the possibility to implement a treatment customized for each patient, while controlling the efficacy of the treatment by anticipating therapeutic escape and other secondary effects inherent in these biotherapies.
BMD offers an innovative line of products with high medical value to monitor:
Prescribed drug (original biological or biosimilar) to optimize dosage consistent with the presence or absence of ADAb.
The presence of anti-drug antibodies (ADAb), of which authors have reported the presence among patients experiencing loss of drug efficacy.
The combination of these parameters allows to anticipate, optimize, and better manage the patients’ treatment.
Also available: a range of quality control sera dedicated to the pharmacological dosage of biotherapies.